(SNY) Sanofi - Overview
Exchange: NASDAQ •
Country: France •
Currency: USD •
Type: Common Stock •
ISIN: US80105N1054
Stock: Vaccines, Immunology, Oncology, Neurology, Rare Diseases
Total Rating 46
Risk 83
Buy Signal -0.65
| Risk 5d forecast | |
|---|---|
| Volatility | 24.1% |
| Relative Tail Risk | -5.41% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.32 |
| Alpha | -19.55 |
| Character TTM | |
|---|---|
| Beta | 0.522 |
| Beta Downside | 0.257 |
| Drawdowns 3y | |
|---|---|
| Max DD | 21.87% |
| CAGR/Max DD | 0.21 |
EPS (Earnings per Share)
Revenue
Description: SNY Sanofi February 24, 2026
Sanofi (NASDAQ: SNY) is a global biopharma company that discovers, develops, manufactures and markets a broad portfolio of therapeutic solutions, including medicines for immunology, rare diseases, neurology, oncology and vaccines such as pediatric, RSV, influenza and travel-related products. The firm leverages an extensive network of collaborations-ranging from small-molecule oncology programs with Exscientia to protein-degrader therapies with Kymera and genome-editing work with Scribe-to expand its pipeline across both biologics and small-molecule modalities.
In FY 2023 Sanofi generated approximately $44.5 billion in revenue, with R&D spending near $7.6 billion, underscoring its commitment to pipeline growth. Q1 2024 sales rose about 4 % year-over-year, driven in part by strong demand for its vaccine franchise amid rising global focus on infectious-disease prevention. The company’s recent collaborations-such as the Exscientia deal targeting up to 15 novel oncology and immunology candidates and the partnership with Denali Therapeutics on inflammatory-disease programs-reflect a sector trend toward leveraging external innovation to accelerate drug development.
For deeper insight, you might explore ValueRay’s analyst notes on SNY.
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income: 7.81b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 2.62 > 1.0 |
| NWC/Revenue: 5.58% < 20% (prev 31.30%; Δ -25.72% < -1%) |
| CFO/TA 0.08 > 3% & CFO 10.75b > Net Income 7.81b |
| Net Debt (12.67b) to EBITDA (12.68b): 1.00 < 3 |
| Current Ratio: 1.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.44b) vs 12m ago -2.65% < -2% |
| Gross Margin: 72.34% > 18% (prev 0.70%; Δ 7163 % > 0.5%) |
| Asset Turnover: 35.99% > 50% (prev 32.30%; Δ 3.69% > 0%) |
| Interest Coverage Ratio: 12.76 > 6 (EBITDA TTM 12.68b / Interest Expense TTM 742.0m) |
Altman Z''
| A: 0.02 (Total Current Assets 30.95b - Total Current Liabilities 28.35b) / Total Assets 126.81b |
| B: error (Retained Earnings missing) |
| C: 0.07 (EBIT TTM 9.47b / Avg Total Assets 129.80b) |
| D: 1.30 (Book Value of Equity 71.38b / Total Liabilities 55.10b) |
Beneish M -3.73
| DSRI: 0.03 (Receivables 396.8m/10.63b, Revenue 46.72b/42.89b) |
| GMI: 0.97 (GM 72.34% / 70.31%) |
| AQI: 1.12 (AQ_t 0.67 / AQ_t-1 0.59) |
| SGI: 1.09 (Revenue 46.72b / 42.89b) |
| TATA: -0.02 (NI 7.81b - CFO 10.75b) / TA 126.81b) |
| Beneish M-Score: -3.73 (Cap -4..+1) = AAA |
What is the price of SNY shares?
As of February 25, 2026, the stock is trading at USD 47.31 with a total of 5,039,791 shares traded.
Over the past week, the price has changed by +1.90%, over one month by -0.04%, over three months by -3.74% and over the past year by -8.08%.
Over the past week, the price has changed by +1.90%, over one month by -0.04%, over three months by -3.74% and over the past year by -8.08%.
Is SNY a buy, sell or hold?
Sanofi has received a consensus analysts rating of 4.18.
Therefore, it is recommended to buy SNY.
- StrongBuy: 5
- Buy: 3
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SNY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 57.7 | 21.9% |
| Analysts Target Price | 57.7 | 21.9% |
SNY Fundamental Data Overview February 21, 2026
P/E Trailing = 19.7417
P/E Forward = 9.2166
P/S = 2.4634
P/B = 1.3111
P/EG = 0.6881
Revenue TTM = 46.72b USD
EBIT TTM = 9.47b USD
EBITDA TTM = 12.68b USD
Long Term Debt = 11.70b USD (from longTermDebt, two quarters ago)
Short Term Debt = 4.61b USD (from shortTermDebt, last quarter)
Debt = 20.33b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.67b USD (from netDebt column, last quarter)
Enterprise Value = 127.75b USD (115.08b + Debt 20.33b - CCE 7.66b)
Interest Coverage Ratio = 12.76 (Ebit TTM 9.47b / Interest Expense TTM 742.0m)
EV/FCF = 15.36x (Enterprise Value 127.75b / FCF TTM 8.32b)
FCF Yield = 6.51% (FCF TTM 8.32b / Enterprise Value 127.75b)
FCF Margin = 17.80% (FCF TTM 8.32b / Revenue TTM 46.72b)
Net Margin = 16.72% (Net Income TTM 7.81b / Revenue TTM 46.72b)
Gross Margin = 72.34% ((Revenue TTM 46.72b - Cost of Revenue TTM 12.92b) / Revenue TTM)
Gross Margin QoQ = 70.26% (prev 74.09%)
Tobins Q-Ratio = 1.01 (Enterprise Value 127.75b / Total Assets 126.81b)
Interest Expense / Debt = 0.49% (Interest Expense 100.6m / Debt 20.33b)
Taxrate = 17.33% (1.04b / 6.02b)
NOPAT = 7.83b (EBIT 9.47b * (1 - 17.33%))
Current Ratio = 1.09 (Total Current Assets 30.95b / Total Current Liabilities 28.35b)
Debt / Equity = 0.28 (Debt 20.33b / totalStockholderEquity, last quarter 71.38b)
Debt / EBITDA = 1.00 (Net Debt 12.67b / EBITDA 12.68b)
Debt / FCF = 1.52 (Net Debt 12.67b / FCF TTM 8.32b)
Total Stockholder Equity = 72.18b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.02% (Net Income 7.81b / Total Assets 126.81b)
RoE = 10.82% (Net Income TTM 7.81b / Total Stockholder Equity 72.18b)
RoCE = 11.29% (EBIT 9.47b / Capital Employed (Equity 72.18b + L.T.Debt 11.70b))
RoIC = 8.48% (NOPAT 7.83b / Invested Capital 92.30b)
WACC = 6.72% (E(115.08b)/V(135.41b) * Re(7.84%) + D(20.33b)/V(135.41b) * Rd(0.49%) * (1-Tc(0.17)))
Discount Rate = 7.84% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -81.65 | Cagr: -1.33%
[DCF] Terminal Value 85.53% ; FCFF base≈7.08b ; Y1≈8.74b ; Y5≈14.88b
[DCF] Fair Price = 134.8 (EV 338.15b - Net Debt 12.67b = Equity 325.48b / Shares 2.42b; r=6.72% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 9.85 | EPS CAGR: 9.46% | SUE: 2.86 | # QB: 1
Revenue Correlation: 4.50 | Revenue CAGR: 5.31% | SUE: 1.24 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.07 | Chg7d=+0.007 | Chg30d=+0.076 | Revisions Net=+1 | Analysts=2
EPS current Year (2026-12-31): EPS=5.00 | Chg7d=-0.010 | Chg30d=+0.102 | Revisions Net=+2 | Growth EPS=+7.1% | Growth Revenue=+6.3%
EPS next Year (2027-12-31): EPS=5.30 | Chg7d=-0.008 | Chg30d=+0.034 | Revisions Net=+0 | Growth EPS=+6.0% | Growth Revenue=+6.2%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.9% (Discount Rate 7.9% - Earnings Yield 5.1%)
[Growth] Growth Spread = -1.6% (Analyst 1.3% - Implied 2.9%)
P/E Forward = 9.2166
P/S = 2.4634
P/B = 1.3111
P/EG = 0.6881
Revenue TTM = 46.72b USD
EBIT TTM = 9.47b USD
EBITDA TTM = 12.68b USD
Long Term Debt = 11.70b USD (from longTermDebt, two quarters ago)
Short Term Debt = 4.61b USD (from shortTermDebt, last quarter)
Debt = 20.33b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.67b USD (from netDebt column, last quarter)
Enterprise Value = 127.75b USD (115.08b + Debt 20.33b - CCE 7.66b)
Interest Coverage Ratio = 12.76 (Ebit TTM 9.47b / Interest Expense TTM 742.0m)
EV/FCF = 15.36x (Enterprise Value 127.75b / FCF TTM 8.32b)
FCF Yield = 6.51% (FCF TTM 8.32b / Enterprise Value 127.75b)
FCF Margin = 17.80% (FCF TTM 8.32b / Revenue TTM 46.72b)
Net Margin = 16.72% (Net Income TTM 7.81b / Revenue TTM 46.72b)
Gross Margin = 72.34% ((Revenue TTM 46.72b - Cost of Revenue TTM 12.92b) / Revenue TTM)
Gross Margin QoQ = 70.26% (prev 74.09%)
Tobins Q-Ratio = 1.01 (Enterprise Value 127.75b / Total Assets 126.81b)
Interest Expense / Debt = 0.49% (Interest Expense 100.6m / Debt 20.33b)
Taxrate = 17.33% (1.04b / 6.02b)
NOPAT = 7.83b (EBIT 9.47b * (1 - 17.33%))
Current Ratio = 1.09 (Total Current Assets 30.95b / Total Current Liabilities 28.35b)
Debt / Equity = 0.28 (Debt 20.33b / totalStockholderEquity, last quarter 71.38b)
Debt / EBITDA = 1.00 (Net Debt 12.67b / EBITDA 12.68b)
Debt / FCF = 1.52 (Net Debt 12.67b / FCF TTM 8.32b)
Total Stockholder Equity = 72.18b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.02% (Net Income 7.81b / Total Assets 126.81b)
RoE = 10.82% (Net Income TTM 7.81b / Total Stockholder Equity 72.18b)
RoCE = 11.29% (EBIT 9.47b / Capital Employed (Equity 72.18b + L.T.Debt 11.70b))
RoIC = 8.48% (NOPAT 7.83b / Invested Capital 92.30b)
WACC = 6.72% (E(115.08b)/V(135.41b) * Re(7.84%) + D(20.33b)/V(135.41b) * Rd(0.49%) * (1-Tc(0.17)))
Discount Rate = 7.84% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -81.65 | Cagr: -1.33%
[DCF] Terminal Value 85.53% ; FCFF base≈7.08b ; Y1≈8.74b ; Y5≈14.88b
[DCF] Fair Price = 134.8 (EV 338.15b - Net Debt 12.67b = Equity 325.48b / Shares 2.42b; r=6.72% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 9.85 | EPS CAGR: 9.46% | SUE: 2.86 | # QB: 1
Revenue Correlation: 4.50 | Revenue CAGR: 5.31% | SUE: 1.24 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.07 | Chg7d=+0.007 | Chg30d=+0.076 | Revisions Net=+1 | Analysts=2
EPS current Year (2026-12-31): EPS=5.00 | Chg7d=-0.010 | Chg30d=+0.102 | Revisions Net=+2 | Growth EPS=+7.1% | Growth Revenue=+6.3%
EPS next Year (2027-12-31): EPS=5.30 | Chg7d=-0.008 | Chg30d=+0.034 | Revisions Net=+0 | Growth EPS=+6.0% | Growth Revenue=+6.2%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.9% (Discount Rate 7.9% - Earnings Yield 5.1%)
[Growth] Growth Spread = -1.6% (Analyst 1.3% - Implied 2.9%)